Provides cord blood banking services, including the processing and long-term cryogenic storage of stem cells from cord blood, cord lining, and cord tissue. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 9% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 1.3× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
The company sells $30.6M a year; the problem isn’t sales — it’s costs running above that number.
There is $40.8M in the vault; even if every debt were paid off, $39.2M would remain.
A loss of $10.0M against $30.6M in annual sales.
The stock sits at $0.15. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.